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Abstract

This study characterized the rates of rates of attention-deficit/hyperactivity disorder (ADHD) in
adolescent and young adult males with fragile X syndrome (FXS) using a multi-method approach
integrating a DSM-based parent interview (Children’s Interview for Psychiatric Syndromes; P-ChIPS,
Fristad et al., 1998) and a parent rating scale (Child Behavior Checklist; CBCL, Achenbach, 2001).
Thirty-one males with FXS, aged 16-24 years, participated. Forty-two percent met DSM-5 criteria for
ADHD and 35% exceeded the CBCL cut-offs. Agreement between the two classification methods was
fair (κ=0.38). Autism symptom severity and nonverbal cognitive ability did not predict ADHD
diagnoses/symptoms. Results show high rates of ADHD in males with FXS during late adolescence and
young adulthood, which are not accounted for by impaired nonverbal cognitive skills or autism symptom
severity. DSM-based ADHD-specific scales are recommended over broadband symptom scales to
improve accurate identification.
Keywords: ADHD, intellectual disability, autism, FMR1
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ADHD in Adolescent and Young Adult Males with Fragile X Syndrome

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder marked by
symptoms of hyperactivity, inattention, impulsivity and executive functioning weaknesses (American
Psychiatric Association, 2013). ADHD is the most commonly diagnosed behavioral disorder in children,
with rates in the general population ranging from 9-11% during childhood to about 4% in adulthood
(Danielson et al., 2018; Kessler et al., 2006). Diagnoses of ADHD are nearly three times more common in
males than females and are associated with a high degree of cooccurrence with other mental, emotional,
and behavioral disorders (Danielson et al., 2018; Reale et al., 2017). The burden of ADHD is significant
and there is great value in research aimed at understanding the nature and course of ADHD. Adverse
outcomes associated with ADHD include higher rates of injury, social difficulties, and reduced
educational and vocational achievement (Harpin et al., 2016; Hinshaw et al., 2012; Kuriyan et al., 2013;
Loe & Feldman, 2007). For the majority of affected individuals, ADHD symptoms persist into adulthood
and are associated with psychiatric comorbidity, substance abuse, criminal activity, failed relationships
and underemployment (Barkley et al., 2004; Biederman et al., 2010; Margherio et al., 2020; Molina et al.,
2018).
Although the precise causal mechanism of ADHD is not clear, the evidence supports a strong
genetic component (Li et al., 2014; Stergiakouli et al., 2012). Recent discoveries have identified clear
genetic overlaps of ADHD to both autism spectrum disorder (ASD) and intellectual disability, and thus,
investigations into the interface between ADHD, ASD, and intellectual disability can advance the field
(Faraone et al., 2017; Ghirardi et al., 2018; May et al., 2018; Pinto et al., 2016; Stergiakouli et al., 2017).
Fragile X syndrome (FXS) may represent a useful genetic model in this regard; FXS is a monogenetic
disorder that is the most common known single-gene cause of ASD and the leading inherited cause of
intellectual disability (Vissers et al., 2016; Waye & Cheng, 2018). FXS is found in about 1:7,000 males
and 1:10,000 females (Hunter et al., 2014) and involves a trinucleotide repeat expansion on the FMR1
gene. FXS is associated with reduced Fragile X Mental Retardation Protein (FMRP), which is involved in
typical brain maturation (Siegel et al., 2017; Zhang et al., 2017). The phenotype of males with FXS is
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marked by nearly universal intellectual disability and about cooccurring ASD observed in approximately
60% of males (García-Nonell et al., 2008; Harris et al., 2008; Klusek, Martin, & Losh, 2014).
ADHD is also a common cooccurring condition associated with FXS, with reported rates in
children with FXS ranging from 35-93%, as reflected in Table 1 (Backes et al., 2000; Bailey et al., 2008;
Bregman et al., 1988; Freund et al., 1993; Hatton et al., 2002; Sullivan et al., 2006; Thurman et al., 2014).
Consistent with the profile of ADHD in the general community, ADHD in FXS emerges during
childhood (Grefer et al., 2016) and is more likely to affect males than females (Newman et al., 2015;
Wheeler et al., 2014). Across studies, the rates of ADHD symptoms and diagnoses in males with FXS are
consistently higher than in the general population without FXS and also higher than those with nonspecific intellectual disability or other known genetic syndromes (Baumgardner et al., 1995; Reilly et al.,
2015). Severity of intellectual impairment does not appear to be associated with the presence or severity
of ADHD (Newman et al., 2015); however, this has not been studied extensively. In studies that have
examined the relationship of ASD to ADHD in FXS, findings are inconsistent with some reports
suggesting that elevated ASD severity is linked with ADHD features (Sullivan et al., 2006), whereas
others suggest that ADHD symptoms are similar across individuals with FXS with or without comorbid
ASD (Hatton et al., 2002; Newman et al., 2015). In a study that included a group of male children with
FXS contrasted to a chronological age, IQ and ASD-severity matched group with non-syndromic ASD,
ADHD symptoms were significantly higher in the group with FXS (Thurman et al., 2014). Inattention,
rather than hyperactivity, appears to be the most prominent feature of ADHD in FXS, with one
investigation of 63 7-13 year-old children with FXS suggesting that 32% exhibited a predominately
inattentive ADHD presentation (ADHD-I), 7% exhibited a hyperactive/impulsive presentation (ADHDH), and 15% exhibited a combined presentation (ADHD-C) (Sullivan et al., 2006). Overall, the evidence
supports FXS as a saturated model for ADHD risk that integrates elevated risk for ADHD within the
context of intellectual disability and ASD.
The presence of ADHD in males with FXS is associated with significant impairment including
reduced prosocial behavior and social functioning (Chromik et al., 2019; Scerif et al., 2012) as well as
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increased family burden (Wheeler et al., 2014). The presence of multiple cooccurring conditions within
FXS is associated with more significant impairment, with intellectual disability, attention problems,
hyperactivity, and anxiety constituting the most common cluster of comorbid disorders in males with FXS
(Bailey et al., 2008). Treatment for ADHD in males with FXS primarily involves medication, with
stimulant medication reported as moderately to highly effective (Berry-Kravis et al., 2012; Hagerman et
al., 1988; Roberts et al., 2011b), and results of a national survey suggest ~30% of people with FXS use
stimulants (Laxman et al., 2018). However, evidence suggests that the attention and thought problems
associated with ADHD do not differ between children with FXS taking medication and those not being
treated, thereby raising questions about medication efficacy (Hatton et al., 2002). Obtaining a better
understanding of the targets and benefits of medication is important because pharmaceutical treatment for
ADHD is a common approach in FXS. These efforts also have implications for clinical trials in which
ADHD-related manifestations of FXS represent common behavioral targets (Berry-Kravis et al., 2013;
Budimirovic et al., 2017).
Although there is an emerging body of research that provides insights into ADHD in FXS, there
are a number of limitations of this work. First, several studies used samples that were highly
heterogeneous including a very broad age range (Gabis et al., 2011; Haessler et al., 2016), inclusion of
participants with the FMR1 premutation (i.e., “carriers” of fragile X) together with those having the full
mutation (Newman et al., 2015), and failure to account for ASD (Frolli et al., 2015; Pegoraro et al., 2014).
In addition, the focus of research to date has largely been on young children with little work specifically
targeting adolescents and young adults. It is unclear from prior research whether individuals with FXS
continue to experience high rates of ADHD symptoms into late adolescence and young adulthood.
Although some studies suggest a general reduction of symptoms across age (Gabis et al., 2011; Haessler
et al., 2016; Wheeler et al., 2014), other reports suggest that the symptoms of ADHD do not abate from
early childhood into adolescence (Newman et al., 2015; Thurman et al., 2014).
A final limitation of the extant literature is that studies to date have not used the revised DSM-5
criteria, and there is a clear over-reliance on broad-based measurement tools that detect a wide range of
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different symptoms and are not specifically targeted at measuring ADHD (Bailey et al., 2008; Grefer et
al., 2016). Although there is value in broad-based measures because they allow for easy detection and
screen for a wide variety of disorders, they often lack specificity for individuals who have comorbid
disabilities such as ASD (Pandolfi et al., 2012). Utilizing ADHD-specific scales and the most recent
DSM-based measures to characterize ADHD in a carefully selected sample is necessary to advance our
understanding of the prevalence of ADHD in males with FXS. This work is critical because ADHD in
FXS is clearly pervasive and interferes with optimal functioning, and documentation of comorbidities
within FXS is essential to directing effective treatment. However, this research is complex given the
presence of co-occurring conditions such as intellectual disability and ASD that challenge differential
diagnostic efforts. Therefore, using homogeneous genetic samples and implementing clearly defined
DSM-based measures will allow for better understanding of true prevalence rates of ADHD in individuals
with FXS. A differential diagnostic approach to known genetic and behaviorally similar
neurodevelopmental disorders, specifically FXS and ADHD, can contribute to the field regarding
diagnostic rates within FXS to allow for more targeted interventions that lead to increased independent
living in this population.
The overall aims of the present study, therefore, were to (1) characterize the rate and presentation
of ADHD diagnoses in youth with FXS using DSM-5 criteria, (2) determine the proportion of youth with
FXS who were reported to have clinical ADHD symptoms on a widely-used parent rating scale, the Child
Behavior Checklist (CBCL), as well as the concordance between CBCL symptom cut-offs and DSM-5
ADHD diagnoses; (3) determine the relationship between ASD symptom severity, nonverbal cognitive
ability, and ADHD diagnoses and symptoms; and (4) describe the use of medication in relation to ADHD
diagnostic status in youth with FXS. We hypothesized that >50% of the youth with FXS would meet
criteria for a diagnosis of ADHD, with more individuals meeting for ADHD-I over the other two
presentations. We expected moderate concordance between the CBCL ADHD scale and DSM-5 ADHD
diagnoses given the concern that broad-based symptoms scales may lack specificity for individuals with
intellectual disability and other comorbidities. We hypothesized that higher levels of ASD symptoms
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would be associated with ADHD diagnoses and symptoms given evidence for shared genetic mechanisms
across ADHD and ASD (Ghirardi et al., 2019; Pinto et al., 2016; Ronald et al., 2008), but that lower
nonverbal cognitive ability would not relate to ADHD, consistent with Newman et al. (2015). We
expected that about half of participants would be using medications targeting ADHD symptoms, with
stimulants being the most common medication type. We expected only moderate alignment between use
of ADHD-targeted medications and ADHD diagnoses, considering prior evidence suggesting a high rate
of stimulant medication use among individuals with FXS without an ADHD diagnosis (Valdovinos et al.,
2009).
Method
Participants
Participants were 31 males with FXS ranging from 16-24 years of age (M = 18.73, SD = 2.13).
Genetic testing was conducted on all participants to confirm the full mutation (>200 CGG repeats on
5’UTR of FMR1). Females were not included in the present study due to the heterogeneous phenotypic
presentation of females with the FXS and the increased clinical involvement in males, which makes
understanding of the extent, nature, and course of cooccurring challenges especially pressing for them
(Bailey et al., 2008). Participants were drawn from a larger longitudinal multi-site study at the University
of California at Davis and the University of South Carolina which focused on language development
during the transition into adulthood (Abbeduto et al., 2019). Inclusionary criteria for the larger study
required that English was the primary language, that the participants consistently used spontaneous twoto three-word utterances, and that they lived at home with their biological mother at study entry. Only
individuals who participated at the University of South Carolina site were included in this study given a
more focused interest on ADHD and the presence of sufficient resources at that site. Recruitment was
conducted nationally through parent listservs, social media, postings by the National Fragile X
Foundation, and with the help of the Research Participant Registry Core of the Carolina Institute for
Developmental Disabilities at the University of North Carolina at Chapel Hill. The annual family incomes
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of the participants ranged from <$20,000 to >$150,000, with the median income reported at $80,000.
Ninety percent of participants were White, 7% were Black or African American, and 3% were Asian.
Procedures
The assessments included in the full protocol were conducted in a university laboratory setting
and lasted two days. The measures for the present study are a subset of those administered. Data
collection occurred based on established procedures of a larger study, including standardized order of test
administration. Administration of the Autism Diagnostic Observation Schedule-Second Edition (ADOS2; Lord et al., 2012) was conducted on the morning of the second day of assessment to allow time for the
participant to establish rapport with the examiner. Parent/caregiver report measures were completed by
the participant’s mother. All measures were completed at the second annual time point of the larger
longitudinal study, except the ADOS-2, which was drawn from the first-year time point. ASD symptoms
were only measured at study entry in the larger study given the relative stability of ASD symptoms in
adolescents with FXS over time (Hernandez et al., 2009). Procedures were approved by the Institutional
Review Board of the University of South Carolina and conform to the ethical standards laid out in the
Declaration of Helsinki. All participants assented to participation, and informed consent was obtained
from the participants’ guardians.
Measures
Children’s Interview for Psychiatric Syndromes–Parent version (PChIPS; Fristad, Teare,
Weller, Weller, & Salmon, 1998). The PChIPS is a DSM-based diagnostic interview that uses a strict
diagnostic criteria model requiring the presence of impairment to assess for the presence of ADHD
symptoms and diagnosis. The PChIPS is a structured parent interview to assess presence of psychiatric
disorders in children and adolescents aged 6-17 years old, which is consistent with the mental age of the
participants enrolled in the present study. It queries symptom count, duration, and impairment consistent
with DSM criteria. Questions pertaining to symptomology are presented and scored in a yes/no format.
The current version of the PChIPS aligns with the DSM-IV; thus, we adapted the assessment to reflect the
updated DSM-5 diagnostic criteria for ADHD, which required two modifications: (1) allowing for the
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concurrent diagnosis of ADHD and ASD, and (2) allowing a retrospective diagnosis to be made if five
symptoms were present before age 12 years. Examiners were trained to administer the PChIPS by a
licensed clinical psychologist. Inter-rater reliability for ADHD presentation classification was calculated
on 20% of randomly selected samples. Percent agreement was 100% between the licensed psychologist
and trained research staff. The categorical distinction of presence/absence of an ADHD disorder based on
DSM-5 criteria served as the primary dependent variable in the analyses. The PChIPS has been applied to
conditions associated with intellectual disability, including Phelan-McDermid syndrome (Shaw et al.,
2011), FXS (Ezell et al., 2018), and ASD (Witwer & Lecavalier, 2010). High item-level agreement (intraclass correlation coefficients of 0.92 for Hyperactive, 0.97 for Inattentive, and 0.93 for Combined) and
fair-to-moderate for diagnostic classification agreement (Hyperactive κ = 0.43, Inattentive κ = 0.60, and
Combined κ = 0.27) has been reported between the PChIPS and the Child and Adolescent Symptom
Inventory (CASI; Gadow & Sprafkin, 2002) in children with ASD (Witwer et al., 2012).
Attention Deficit/Hyperactivity Problems Scale, Child Behavior Checklist (ADHD Scale,
CBCL; Achenbach, 2001) was administered and is a widely used broad-based measure of child emotional
and behavioral problems that provides an index of ADHD symptoms. The CBCL is a well-established
118-item parent-report tool that has good reliability and validity and has been widely used in
neurodevelopmental disabilities research including FXS. The Attention Deficit/Hyperactivity Problems
DSM-oriented subscale consists of 7-items and was designed to align with the symptoms of ADHD as
outlined in the DSM. T-scores were computed and used to determine whether individual participants
exceeded cut-offs for clinically significant ADHD symptoms; scores of 65-69 are considered “borderline
clinical” and scores of 70+ are considered clinically significant. The 6-18 year old CBCL form for was
used for all participants and 18-year norms were used to calculate standard scores for participants older
than 18, consistent with prior work (Chromik et al., 2019; Roberts et al., 2019; Roberts et al., 2018). The
6-18 form was used for all participants because the items were thought to be more appropriate for the
developmental level of young adults with FXS than is the adult form.
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Autism Diagnostic Observation Schedule-Second Edition (ADOS-2; Lord et al., 2012). The
ADOS-2 was administered to determine ASD status and the severity of ASD symptoms. The ADOS-2
consists of a series of semi-structured interviews and play opportunities between an examiner and a
participant, allowing for the observation of developmentally appropriate and inappropriate responses to
these social exchanges. A continuous index of ASD symptoms, as reflected by the ADOS-2 calibrated
severity score, was also computed per the test instructions (Lord et al., 2012). Participants were
administered the ADOS-2 module appropriate for their expressive language level and chronological age
as specified by the administration manual, with modules 1, 2, and 3 represented in the present sample.
The ADOS-2 was administered and scored live by graduate-level professionals who completed standard
research reliability training. Ten percent of the administrations were randomly selected and second-scored
by video for inter-reliability, with percent agreement above 80% across all items and algorithm items.
Twenty-three participants (74.2%) exceeded the threshold for ASD.
Brief IQ, Leiter-R (Roid & Miller, 1997). The Brief IQ of the Leiter-R is a nonverbal
intelligence measure that has strong psychometric properties and is appropriate for use with individuals
who have limited receptive and expressive language capabilities. Growth scale value scores, which reflect
a transformation of raw scores into an equal-interval Rasch scale, were used in analysis to mitigate
problems associated with floor effects in the standard scores.
Medications Targeting ADHD Symptoms. Information on medication use was gathered as part
of a standard demographic form for the larger study. The use of medications targeting ADHD symptoms
was characterized as a bivariate present/absent variable. For the current study, any medication indicated
by caregivers as targeting ADHD, attention, or hyperactivity was included (all such medications fell into
the drug classes of stimulants or alpha-2 adrenergic agonists, such as guanfacine).
Statistical Analyses
Descriptive statistics were computed and are presented in Table 2. Variables were examined for
normal distribution with no need for corrections indicated. A correlation matrix was computed to
understand the relationship among variables to inform model specification (Table 3). Chronological age
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was not associated with the ADHD variables and, therefore, was not covaried in statistical models. To
address the first research question regarding the rate and presentation of ADHD, the proportion of
individuals who met DSM-5 diagnostic criteria for ADHD on the PChIPS was computed, as was the
percentage of individuals meeting criteria for each ADHD presentation. The second research question was
addressed by computing the percentage of individuals who obtained borderline or clinical scores on the
CBCL ADHD scale. Cohen’s kappa (κ; Cohen, 1960), a measure of nominal scale agreement between
two categorization of responses commonly used as a measure of classification accuracy (Kwiecien et al.,
2011), was obtained to evaluate the concordance between DSM-5 ADHD diagnoses and the CBCL
ADHD scale cut-offs. Concordance between the two measures was also examined descriptively by
computing the percent of individuals who did/did not obtain borderline/clinical scores on the ADHD
CBCL scale to those who did/did not meet diagnostic criteria for ADHD. Our third research question
regarding the relationship between ASD symptom severity, nonverbal cognitive ability, and ADHD
diagnoses and symptoms was tested by fitting two logistic regression models that included the ADOS-2
calibrated severity score and the Leiter-R growth scale value scores as predictors of either DSM-5 ADHD
diagnoses or the CBCL ADHD subscale cut-off classification. Additionally, to test relationships with
continuous ADHD symptoms, a general linear model with fit to test the ADOS-2 calibrated severity score
and the Leiter-R growth scale value as predictors of the CBCL ADHD subscale T-score. To address the
final research question about medication use, the proportion of participants taking medications targeting
ADHD symptoms was computed. All analyses were conducted using SAS software, version 9.4, (SAS
Institute Inc., Cary, NC).
Results
Rate of DSM-5 ADHD Diagnoses and Presentations. Thirteen of 31, or 41.9%, of the youth
with FXS met DSM-5 diagnostic criteria for ADHD on the PChIPS. Of those who met criteria for ADHD,
69.2% (9/13) exhibited an ADHD-I presentation, 15.4% (2/13) exhibited an ADHD-H, and 15.4% (2/13)
exhibited ADHD-C. See Figure 1.
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Percent of Individuals Exceeding the CBCL ADHD Scale Cut-offs. Ten of 31, or 32.3%, of
the youth with FXS exceeded the CBCL ADHD cut-offs. Of these 10, 5 (16% of the total sample)
obtained borderline scores and 5 (16% of the total sample) obtained scores in the clinical range.
Concordance Between DSM-5 ADHD Diagnosis and CBCL ADHD Cut-offs. Cohen’s kappa
was calculated at κ = 0.38 (95% CI 0.06, 0.71), which is consistent with “fair” levels of agreement
(Cohen, 1960). DSM-5 diagnoses and the CBCL ADHD scale cut-offs were concordant for 70.8% of the
sample (22/31), see Table 4. Of those who met DSM-5 criteria for ADHD per the PChIPS clinical
interview, 53.8% (7/13) also scored within the borderline or clinical range on the CBCL ADHD scale.
The majority of individuals who did not meet diagnostic criteria for ADHD also obtained CBCL scores
that were below cut-offs, 83.3% (15/18). DSM-5 diagnoses and the CBCL ADHD scale cut-offs were
disconcordant for 29.0% of the sample: 19.4% met DSM-5 criteria for ADHD but did not score in the
borderline/clinical range for ADHD on the CBCL, and 9.6% scored above CBCL cut-offs but did not
meet DSM-5 criteria for ADHD.
ASD Symptom Severity and Nonverbal Cognitive Ability as Predictors of ADHD Diagnoses
and Symptoms. The results of the logistic regression model indicated that neither ASD symptom severity
(χ2 [1] = 0.02, p = .878, OR = 1.36) nor nonverbal cognitive ability (χ2 [1] = 1.74, p = .187, OR = 1.14)
were significant predictors of DSM-5 diagnostic criteria for ADHD on the PChIPS. Similarly, neither
ASD symptom severity (χ2 [1] = 0.43, p = .510, OR = 1.26) nor nonverbal cognitive ability (χ2 [1] =
0.72, p = .396, OR = 1.10) were associated with increased odds of scoring above the cut-off for ADHD on
the CBCL. Regression analyses also indicated that the combined influence of ASD symptom severity and
nonverbal cognitive ability did not account for significant variance in continuous ADHD subscale Tscores on the CBCL, F (2,28) = 0.05, p = 0.952, R2 < 0.01.
Frequency of Medication Use Targeting ADHD Symptoms. Of the 31 individuals with FXS,
15 (48.4%) were taking medications that target ADHD symptoms. Nine of the 15 were taking stimulant
medications. Of the 15 individuals using medications targeting ADHD symptoms, roughly half (53.3%, n
= 7) met criteria for DSM-5 ADHD.
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Discussion

FXS may serve as a saturated genetic model for ADHD, based on evidence of genetic overlap
between intellectual disability, ASD, and ADHD, with prior research focused on children with FXS
suggesting that ADHD is a highly prevalent and impairing cooccurring condition. Extending prior work
focused on children, the present study investigated the rates, presentation, and correlates of ADHD in
FXS during late adolescence and young adulthood, applying both DSM-5 diagnostic criteria as well as
broadband parent rating scales. Forty-two percent of the adolescent and young-adult males with FXS in
this study met DSM-5 criteria for ADHD, with neither intellectual disability nor ASD symptom severity
predicting ADHD diagnostic outcome or symptoms. Concordance between DSM-5 diagnoses and cutoffs on the ADHD subscale of the CBCL was fair, yielding a concordant ADHD classification for 71% of
the sample. Nearly half of the participants were using medications that target ADHD symptoms, although
only half of those using ADHD medications met DSM-5 criteria for ADHD. Through inclusion of a
relatively homogeneous sample of 16- to 24-year-old males with FXS, the majority of whom exhibited IQ
scores consistent with moderate intellectual disability, this report describes for practitioners the expected
rates of ADHD co-occurrence in this subpopulation and informs methods for evaluating ADHD for
improved identification and access to interventions.
Elevated Rate and Presentation of ADHD in Adolescent/Young Adult Males with FXS
Prevalence rates of ADHD can vary greatly across diagnostic methods, necessitating focused
study to clarify baseline rates of ADHD in individuals with FXS. The present study is the first to apply
DSM-5 diagnostic criteria to determine ADHD diagnoses in adolescent and young adult males with FXS.
Focused investigations of the adolescent/young adult period in FXS are critical as this developmental
period tends to be marked by heightened psychopathological risk in the general population (Rutter, 2007).
Forty-two percent of the sample met criteria for ADHD, which is in line with previous diagnostic
studies of children with FXS that have reported rates between 35-74% using earlier versions of the DSM
(Backes et al., 2000; Sullivan et al., 2006). Therefore, our data support the notion that ADHD continues to
represent a significant comorbidity in FXS into early adulthood, at rates that significantly exceed that of
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the general population. Although some previous research has suggested abatement of ADHD symptoms
in FXS with age (Gabis et al., 2011; Wheeler et al., 2014), the results of the current study indicate that
ADHD symptoms in adolescents and young adults exceed diagnostic thresholds at at rates comparable to
the rates that have been reported in children. It is possible that symptoms improve with age but continue
to exceed diagnostic thresholds—a possibility that remains to be addressed in future longitudinal work
tracking intraindividual change in symptoms and diagnoses across time.
ADHD-I was the most prevalent ADHD presentation, with 29% of the sample exhibiting ADHDI, 6% ADHD-H, and 6% ADHD-C. Rates of the ADHD presentations align with previous research
employing DSM-IV criteria in younger and/or more heterogeneous samples. Sullivan et al. (2006) also
observed ADHD-I as the dominant presentation in a sample of 7-13 year-old boys and girls with FXS (n
= 57); ADHD-I was observed in 32% the sample, ADHD-I in 7%, and ADHD-C in 15%. Similarly, Gabis
et al. (2011) detected ADHD-I in 27%, ADHD-H in 13%, and ADHD-C in 7% of an older but smaller
sample of 15 males and females with FXS, aged 12-29 years. Corroborating and building these earlier
reports using DSM-5 criteria in a more homogeneous sample of males aged 16-24 years, we found that
ADHD in adolescent and young adult males with FXS is overwhelmingly characterized by the inattentive
symptoms (69% of those who met criteria for ADHD exhibited ADHD-I, and an additional 15% met
criteria for ADHD-C). Characterizing ADHD presentation within FXS is of relevance because those
presentations are associated with different clinical needs. Relative to ADHD-H, children with ADHD-I
are more likely to show social isolation, experience comorbid anxiety and depression, and experience
learning and reading difficulties (Baeyens et al., 2006; Paloyelis et al., 2010; Willcutt et al., 2001;
Willcutt et al., 2007). In clinical samples, hyperactivity/impulsivity symptoms also tend to improve with
age, whereas inattention symptoms are more likely to persist across development (Hurtig et al., 2007).
No Association With Nonverbal Cognitive Ability or ASD Symptoms
We did not detect an association between ASD symptom severity and ADHD diagnoses or
symptoms. Findings on the relations between ASD symptoms/comorbidity and attention problems in
children with FXS have been conflicting, with differences in the samples and methodologies making it
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difficult to tease apart the source of discrepancies across reports. Some cross-sectional reports have not
detected a relationship between ADHD and ASD symptoms in FXS (Hatton et al., 2002; Newman et al.,
2015) and emerging longitudinal evidence suggests that clinical ADHD symptoms in school-aged boys
with FXS remain high and stable across time regardless of whether cooccurring ASD features are also
present (Cornish et al., 2013). In contrast, other studies have reported association between ADHD and
ASD symptoms in individuals with FXS (Doherty et al., 2020; Smith et al., 2012). In this report, we did
not find evidence that ASD symptoms translated to heightened ADHD symptoms or higher likelihood of
an ADHD diagnosis in adolescents and young adults with FXS.
Nonverbal cognitive ability was not associated with ADHD symptoms or diagnoses, which aligns
with the findings of Newman et al. (2015). Understanding the relationship between ADHD and
intellectual disability within the context of FXS, or the lack thereof, has implications for diagnostic
practices with regard to the phenomenon of diagnostic overshadowing (e.g., when intellectual disability
“overshadows” the presence of comorbid conditions such as ADHD, leading to reduced clinical
recognition and treatment of concomitant disorders; Mason & Scior, 2004; White et al., 1995). In the
present study, ADHD symptoms and diagnoses were not related to differences in IQ, which lends validity
to the ADHD diagnosis in FXS and highlights the need for caution when conceptualizing ADHD
symptoms in this group as features that are inherent to the presence of intellectual disability. The
identification of ADHD in individuals with FXS is critical to facilitating access to interventions that have
the potential to improve quality of life.
Implications for the Assessment of ADHD Within Individuals With FXS
This report provides broad support for the utility of the PChIPS for use in FXS, while also
underscoring the need for further formal psychometric investigation to validate the PChIPS for use in
intellectual and developmental disabilities. Several investigations have now successfully applied the
PChIPS to characterize mental health disorders in children with various forms of intellectual and
developmental disabilities (Ezell et al., 2018; Shaw et al., 2011; Witwer & Lecavalier, 2010), including a
psychometric study by Witwer et al. (2012) that found good reliability and support for concurrent validity
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when applying the PChIPS to a sample of children with ASD. Interestingly, the PChIPS showed excellent
agreement with the CASI for item-level ADHD symptoms, while concordance between the two measures
for ADHD diagnostic outcome was only fair. Witwer et al. (2012) speculated that diagnostic
discrepancies may have been related to the challenges of capturing impairment associated with ADHD
within a population that also experiences concomitant behavioral difficulties related to ASD (i.e.,
caregivers may be less reliable in recognizing and endorsing ADHD-related impairment when their child
experiences pervasive impairment related to other cooccurring conditions). Notably, however, the PChIPS
and CASI were not more discordant in subgroups of children with ASD with IQs above or below 70,
suggesting that the PChIPS performed equivocally in children with and without cooccurring intellectual
disability (Witwer et al., 2012). While more psychometric work is needed, the present report builds on
evidence that the PChIPS can be successfully applied to populations with intellectual disability.
The present study also has implications for the use of the CBCL to characterize ADHD in FXS.
The CBCL is a widely-used broadband symptom scale that shows moderate sensitivity and specificity for
identifying ADHD in clinical and community settings (Chang et al., 2016). However, the CBCL has also
been suggested to lack specificity for individuals with co-occurring disorders (Pandolfi et al., 2012) and,
therefore, may result in overestimation of ADHD rates in FXS relative. We found that the Kappa
classification agreement between the CBCL ADHD cut-offs and DSM-5 diagnoses determined via the
PChIPS were only fair in this sample of adolescents and young adults with FXS. The CBCL missed 19%
of those who met DSM-5 criteria for ADHD. Compared to the 42% rate of ADHD determined via the
DSM-5, 32% of the sample exceeded the CBCL cut-off scores for ADHD when considering both
borderline and clinical scores as elevated. When only clinical CBCL scores were considered, just 16% of
the sample exceeded cut-offs. These findings closely mirror the results of Sullivan et al.’s (2006) study of
children with FXS in which only 6% of the sample exceeded CBCL ADHD clinical cut-offs, compared to
53% when parents completed a DSM-IV-based ADHD symptom inventory. Together, these findings
suggest under-identification of ADHD in FXS via the CBCL, rather than over-identification. Therefore,
caution should be exercised when relying on the CBCL to characterize ADHD in individuals with FXS;
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the use of a DSM-based ADHD-specific interview/symptom inventory appears to improve identification
accuracy. When employing the CBCL, both borderline and clinical scores should be considered, as
reliance on only the clinical scores resulted in gross underestimation of ADHD rates in both the present
study and in the Sullivan et al. (2006) report.
Medication Use
Nearly half of the adolescents and young adults in this study were using ADHD-targeted
medications, which is similar to rates of medication usage found in previous research (Roberts et al.,
2011a). Stimulants were the most commonly used drug class to target ADHD, which is notable given that
stimulants are poorly tolerated in FXS—they represent the psychotropic medication that is most likely to
be discontinued, with common side effects of anxiety, irritability, and mood lability (Berry-Kravis &
Potanos, 2004; Valdovinos et al., 2009). Interestingly, about half of the participants who were using
ADHD-targeted medications did not meet diagnostic criteria for ADHD. The reason for this is unclear,
although it could reflect use of stimulant medications in individuals with FXS who display some
subthreshold symptoms of ADHD. It is also possible that ADHD-targeted medications were prescribed to
treat symptoms other than ADHD; for example, a nation-wide survey by Valdovinos et al. (2009) found
surprisingly high rates of stimulant use in individuals with FXS who had difficulty with anxiety.
Although medication is typically the first course of intervention for individuals with FXS who exhibit
ADHD, future research should examine the utility of a combined pharmaceutical and behavioral
approach, as this approach is typically most effective in the management of ADHD outside of the context
of FXS (Parens & Johnston, 2009; Pelham et al., 2000).
Strengths, Limitations, and Directions
Strengths of the present study include the narrow, well-defined sample of individuals with FXS,
who were all males with intellectual disability falling between the ages of 16- to 21 years. Although a
trade-off to the inclusion of such a homogenous sample was a more limited sample size of 31 individuals,
the focused sample clarifies the expected ADHD profile in males with FXS during adolescence and
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young adulthood, specifically. The use of a DSM-based diagnostic interview to evaluate the presences of
ADHD is also a strength, and this is the first report to apply the new DSM-5 criteria to a FXS sample.
There are a number of measurement considerations. First, our multimethod approach
incorporating both the PChIPS and the CBCL is a strength. However, it should be acknowledged that
differential diagnosis of ADHD in a clinical setting would involve multiple sources of information (parent
and teacher report data, behavioral measures, etc) paired with professional clinical judgement. Therefore,
our determination of ADHD status is still limited relative to a thorough clinical evaluation. Additionally,
our use of parent report can be viewed as a limitation as parent perceptions of impairment can be skewed
due to the significant level of impairment in children with intellectual disability and particularly
individuals with FXS. However, self-reported behaviors were not an option in this FXS sample due to
intellectual disability and low language skills. Future studies pairing parent-report data with clinical
observation or teacher-report data may help mitigate rater biases. Another limitation was our use of the
CBCL 6-18 form for all participants; 13 participants were above the age range of the norming sample.
Although this approach is consistent with prior work (Chromik et al., 2019; Roberts et al., 2019; Roberts
et al., 2018) and appropriate given the developmental level of the participants, it should be acknowledged
that the standard scores for the older participants may have decreased validity.
Conclusions
ADHD continues to represent a significant comorbidity in FXS through the adolescent and young
adult years, with 42% of 16- to 21-year-old males in the present study meeting DSM-5 criteria for
ADHD. Evaluation of ADHD via the CBCL yielded lower rates of ADHD and classification agreement
between the DSM-5 and CBCL ADHD subscale was only fair, suggesting that overreliance on the CBCL
may result in under-characterization of ADHD symptoms in FXS. ADHD diagnoses and symptoms were
not predicted by low IQ or the presence of ASD symptoms in this sample of males with FXS, which has
implications for the phenomenon of “diagnostic overshadowing,” or the clinical tendency to overlook
comorbid conditions in the presence of intellectual disability. This report describes for practitioners the
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expected rates of ADHD in adolescent and young adult males with FXS and ADHD measurement in this
group, in efforts to facilitating access to interventions and improve quality of life.
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Table 1
Reported Rates of ADHD in Individuals with FXS
Authors (Year)

n

Age

Sex
(M:F)

Measure

Rate
of
ADHD

Studies Utilizing Diagnostic Indices of ADHD
Backes , Genç,
Schreck, Doerfler,
Lehmkuhl, & Von
Gontard (2000)
Baumgardner, Reiss,
Freund, & Abrams
(1995)
Freund, Reiss, &
Abrams (1993)
Pegoraro, Steiner.,
Celeri, Banzato &
Dalgalarrondo (2014)
Sullivan, Hatton,
Hammer, Sideris,
Hooper, Ornstein, &
Bailey (2006)

49

5 – 16 years
(M = 9 years)

49:0

Kinder-DIPSa

74%

31

3 – 18 years
(M = 8 years)

31:0

DSM -IIIb

73%

17

4 – 27 years

0:17

Diagnostic Interview for Children and Adolescents
(DICA)-Parent Versionc

35%

13

6 – 16 years
(M = 12 years)

12:1

DSM-IV-TRd

77%

54:5

Childhood Symptom Inventory–4 (CSI-4), Parent
Checkliste or Adolescent Symptom Inventory -4
(ASI-4), Parent Checklistf
Childhood Symptom Inventory–4 (CSI-4), Teacher
Checkliste or Adolescent Symptom Inventory -4
(ASI-4), Teacher Checklistf

59

7 – 13 years
(M =10 years)

54%

59%

Studies Utilizing Screening/Symptom Rating Scale Indices of ADHD
Baumgardner, Reiss,
Freund, & Abrams
(1995)

31

Cornish, Cole,
Longhi, KarmiloffSmith, & Scerif
(2013)
Grefer, Flory,
Cornish, Hatton, &
Roberts (2016)
Hatton, Hooper,
Bailey, Skinner,
Sullivan, & Wheeler
(2002)
Newman, Leader,
Chen, & Mannion
(2015)

Aberrant Behavior Checklist (ABC) Hyperactivity
Scale, Parent Reportg
Aberrant Behavior Checklist (ABC) Hyperactivity
Scale, Teacher Reportg

40%

3 – 18 years
(M = 8 years)

31:0

46

58 – 133
months
(M = 9 years)

46:0

Conner’s Teacher Rating Scale – Revised: Short
Formh

33

36 – 55
months
(M = 41
months)

33:0

CBCL Attention/Hyperactivity DSM-oriented
Subscale, Parent Report Formi (reported rate does
not include borderline scores)

59

48 - 152
months
(M = 87
months)

59:0

CBCL Attention Problems Subscale, Parent Report
Formi (reported rate includes borderline scores)

56%

47

2 – 17 years
(M = 8 years)

35:12

Conners-3 Inattention and Hyperactivity/Impulsivity
Subscales, Parent Short Versionj & Conners Early
Childhood, Parent Short Versionj

83%

Note. aSchneider et al. (1995); bAmerican Psychiatric Association (1980); cReich (2000); dAmerican
Psychiatric Association (2000); eGadow and Sprafkin (1997); f Gadow et al. (1997); gAman et al. (1985);
h
Conners (1997); iAchenbach (2001); jConners (2008); jConners (2009)

50%

43%

9%
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Table 2
Descriptive Statistics
Variable
Brief IQ Standard Score, Leiter-R

M (SD)
Range
38.97 (5.39)
36.00-56.00

Brief IQ Growth Scale Value, Leiter-R

459.90 (14.27)
420.00-488.00

ASD Severity Score, ADOS-2

5.68 (2.31)
1.00-10.00

ADHD Scale T Score, CBCL

58.87 (2.13)
50.0-73.0
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Table 3
Correlation Matrix

DSM-5 ADHD
Diagnosis
ADHD Scale T
Score, CBCL
ASD Severity
Score, ADOS-2
Brief IQ
Growth Scale
Value Score,
Leiter-R
Chronological
Age
*p< .050

DSM-5
ADHD
Diagnosis

ADHD
Scale T
Score,
CBCL

ASD
Severity
Score,
ADOS-2

Brief IQ
Growth
Scale Value,
Leiter-R

Chronological
Age

---

.40*

-.11

.27

.07

---

-.01

.06

.12

---

-.31

-.16

---

.43*

---
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Table 4
Number of Individuals Meeting Criteria for a DSM-5 ADHD Diagnosis in Comparison to CBCL
ADHD Cut-offs

Range of CBCL ADHD Scale T-Score
Clinical
Borderline
Normal
Total

DSM-5 ADHD Diagnosis
Positive (n)
Negative (n)
4
1
3
2
6
15
13
18
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Figure 1
Percent of Youth with FXS Meeting Criteria for ADHD
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